The MPP And Merck Partner For Molnupiravir In Lower-Income Countries

As MPP Looks To Further License Non-Exclusive Sublicenses To Manufacturers

 
• By Akriti Seth

The Medicines Patent Pool has signed its first agreement to provide access for a COVID-19 medical technology with Merck & Co, to increase access of generic molnupiravir to 150 lower income countries. 

Molnupiravir
Partners look to increase access of generic molnupiravir to 150 lower income countries • Source: Alamy

The Medicines Patent Pool has partnered with Merck & Co., Inc.to increase access to the investigational oral antiviral COVID-19 drug molnupiravir in 105 low- and middle-income countries. 

Merck noted that it is jointly developing molnupiravir – indicated for treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization - with infectious diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business